However, emerging evidence suggests the potential of pharmacological agents like statins, ezetimibe, PCSK9 inhibitors, PPAR agonists, and bempedoic acid in addressing the underlying metabolic abnormalities associated with MASLD. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.